Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC

Did you know prior CDK4/6 duration may be prognostic for identifying patients more likely to benefit from single-agent oral SERDs? Credit available for this activity expires: 04/07/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46?ecd=bdc_podcast_libsyn_mscpedu